Combination therapy reduces JAK2/STAT5 and CRKL activities, induces apoptosis, inhibits proliferation and colony growth, and eliminates CML LSCs in vitro. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.